Get it on Google Play

Eisai completes FDA submission for subcutaneous Alzheimer's treatment

November 25, 2025 7:31 AM EST Send to a Friend
Eisai Co., Ltd. (Tokyo: 4523) and Biogen Inc. (NASDAQ: BIIB) announced that Eisai has completed its rolling submission to the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login